The Short Answer
AptarGroup stock (ATR) is qualitatively halal, but quantitatively incomplete on this current screen. Aptar is a global supplier of dispensing, sealing, and material-science solutions across pharmaceutical, beauty, and consumer markets.
Dispensing-systems, drug-delivery-systems, and packaging-closures manufacturing are unambiguously permissible at the activity level. The March 31, 2026 filing reports debt/assets of 23.94%, liquidity/assets of 4.50%, and receivables-plus-cash/assets of 20.71%; the known financial ratios pass, but no universal prohibited-revenue numerator is disclosed.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
1,220.503 / 5,097.783
229.477 / 5,097.783
1,055.797 / 5,097.783
3.642 / 982.868
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 23.94%, liquidity/assets is 4.50%, receivables-plus-cash/assets is 20.71% and disclosed interest income is 0.37%; known financial ratios pass, but the activity numerator is incomplete.
- Financial
- Pass
- Overall
- Incomplete
Known asset-based ratios are below the examined MSCI limits; the business-activity numerator remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Known debt and liquidity ratios pass the examined Malaysia limits; this is not an official classification and prohibited activity is not separately quantified.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; the total-assets ratios are shown separately.
Business-activity disclosure
AptarGroup manufactures dispensing, sealing, drug-delivery and packaging systems. The core activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for all end markets and end-product uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; no end-product estimate is invented.
Purification
Aptar discloses $3.642 million of investment-income interest, but no scholar-specific purification percentage is asserted and the activity numerator remains incomplete.
Inputs, assumptions and primary sources
- Amounts are USD millions from AptarGroup's March 31, 2026 Form 10-Q.
- Debt combines $1,176.490 million of long-term obligations including current maturities and $44.013 million of operating-lease liabilities; capital leases are included in the long-term-obligations presentation.
- Cash and cash equivalents are $222.529 million and short-term investments are $6.948 million. Equity investments are excluded from interest-bearing securities.
- Accounts notes and loans receivable are $833.268 million and first-quarter revenue is $982.868 million.
- Aptar reports $3.642 million of investment-income interest for the quarter (0.37% of revenue). No universal prohibited-revenue numerator is disclosed.
- Pharma drug-delivery, beauty dispensing and closures are generally permissible component-manufacturing activities, while end-product categories remain qualitative context.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
Aptar's Business Activity
AptarGroup operates through three reporting segments:
- Aptar Pharma: Drug-delivery-systems including nasal-spray-pumps, metered-dose-inhaler-valves, and injectables-components
- Aptar Beauty: Dispensing-and-sealing solutions for beauty-and-personal-care products such as pumps, closures, and sprayers
- Aptar Closures: Dispensing-closures and sealing-solutions for food, beverage, and home-care products
These are general-purpose packaging-and-delivery-components businesses — manufacturing physical dispensing and sealing systems. This is permissible at the activity level.
Concerns to Be Aware Of
1. End-Market Look-Through
A portion of Beauty-segment components is used in fragrance-and-cosmetics products, and some closures are used by beverage customers whose own product mix varies. Under standard methodology the component manufacturer is screened on its own permissible activity rather than the look-through end-product, but stricter investors may wish to review end-market exposure.
2. Leverage Profile
Aptar reports $1,220.503 million of debt and lease liabilities against $5,097.783 million of assets (23.94%). The known total-assets debt ratio passes the displayed tests; a licensed market-cap denominator is not stored in this screen.
3. Minor Interest Income
Aptar reports $3.642 million of investment-income interest for the quarter (0.37% of revenue). No fixed purification percentage is invented; investors should follow their chosen scholar or methodology.
Filing-Based Ratios (March 31, 2026)
Based on Aptar's latest Form 10-Q and consolidated financial statements:
- Debt / assets: 23.94%, below the examined 33.333% limit.
- Cash + interest-bearing securities / assets: 4.50%, below the examined liquidity limit.
- Receivables + cash / assets: 20.71%, below the examined asset-based limits.
- Disclosed investment-income interest / revenue: 0.37%.
- Prohibited-activity revenue: Not separately disclosed; component end-market exposure remains qualitative context.
Methodology Interpretation
The known asset-based ratios and disclosed interest-income ratio pass the examined tests, while the business-activity numerator remains incomplete. The overall result is incomplete for this screen; it is not a claim about any external agency or a universal scholarly ruling.
Bottom Line
AptarGroup (ATR) is qualitatively halal but quantitatively incomplete on this current screen. The core business — dispensing, sealing, and drug-delivery systems — is unambiguously permissible at the activity level, with a high-quality recurring pharma-components base. The main diligence item is the component end-market mix.
For Muslim investors seeking packaging-and-healthcare-components exposure, ATR sits alongside other halal-screened names like Becton Dickinson (BDX) and West Pharmaceutical Services (WST).
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →